According to BlockBeats news, on August 21, data from the market showed that the U.S. stock BNB treasury company Windtree Therapeutics (WINT) received a notice from Nasdaq on August 19, 2025, stating that its stock price had remained below $1 for too long (Rule 5550(a)(2)), and after multiple reverse splits and not meeting the usual grace period, its common stock would be delisted from the Nasdaq capital market and transitioned to OTC market trading on August 21. This news caused its stock price to start declining early this morning, ultimately closing down 77.21%, with a market value of only $3.152 million.
It is worth noting that the stock price of WINT has maintained a textbook-like 'zeroing' trend over the past year. On August 22 last year, the stock price was $517.5, and it has since accumulated a decline of 99.98%. On February 21 this year, the opening price was $4.68, and it has since accumulated a decline of 97.8%. After the announcement of the BNB treasury strategy a month ago, the stock saw a significant increase in trading volume over several trading days (including several trading days before the announcement) and eventually reached a recent high of $1.28 on July 18, before starting a downward trend again, accumulating a decline of 91.4% to date.
It is reported that Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company, with several medical projects still in clinical stages and far from commercialization. According to the latest data, the company's net income for the most recent quarter was -10.64 million dollars, compared to -4.04 million dollars in the previous quarter, representing an increase in losses of 163.04%. The company initially announced the launch of the BNB treasury strategy on July 16, aiming to raise $60 million through a securities subscription. On July 25, it announced that it had signed a new financing agreement of $520 million to purchase BNB.